This conversation looks at a startup tackling a precise operational choke point: medication-adherence outreach in U.S. ambulatory care and pharmacy settings. Instead of promising to “fix the EMR,” Rivvi positions itself around the messy, human workflows that sit beside it – call lists, spreadsheets, payer feeds – and uses conversational AI to turn those inputs into structured, attributable actions.
Author: Lidziya Tarasenka
Lidziya Tarasenka
Healthcare professional with a strong background in medical journalism, media redaction, and fact-checking healthcare information. Medical advisor skilled in research, content creation, and policy analysis. Expertise in identifying systemic healthcare issues, drafting reports, and ensuring the accuracy of medical content for public and professional audiences.
We live in a world where data means a lot. But what if some of that data only creates the illusion of control, while actually making it harder to make decisions? This uncomfortable truth was explored in depth by Irina McLean, Health and Social Care Research Coordinator at NHS Research Scotland.
In 2022, 74.4% of U.S. physicians worked in practices that used telehealth, underscoring how routine virtual care has become. “No Access” – Medicare coverage at risk. Unless Congress acts, on Oct 1, 2025 Medicare’s pandemic-era flexibilities for non-behavioral telehealth from the home expire.
Like other sectors, healthcare is rapidly undergoing digital transformation. According to a forecast by Roland Berger, the global digital health market could grow to €1 trillion by 2026, with €59 billion projected in Germany. However, regardless of technological progress, digital innovations should prioritize empathy and compassion.
VIZZ eye drops improve vision within minutes. Mechanism, trials, and what to watch. FDA-approved aceclidine 1.44% eye drops to improve near vision in presbyopia. Once daily: 1 drop/eye, wait 2 min, then a 2nd drop from a single-use, preservative-free vial. Effect observed within ~30–180 min and measured up to 10 hours.
The past few years have felt like a rolling earthquake, triggered by an explosion of new technologies across every field, and healthcare is no exception. Digital tools, AI, “game-changing” apps, and biotechnology breakthroughs promise to revolutionize patient care.
Artificial intelligence has already made significant advances. It really hasn’t been long since we discovered the immense benefits of generative AI with the launch of ChatGPT. But with agentic artificial intelligence, a new chapter is beginning. Systems that can operate on their own open new opportunities for efficiency, automation, and innovation.
The wave of COVID-19, coupled with its shocks, new social practices, and economic troubles, exerted an array of beneficial influences on the world of HealthTech. The urgent need for solutions, capable of assisting doctors with handling a seemingly never-ending influx of patients in a time-saving, distant, and accurate fashion, boosted the progress of tools in several areas.
The market for medical software is booming, but behind this growth lie growing risks. In the race for hypergrowth, both startups and large companies are increasingly launching products before fully validating their safety and effectiveness. This approach allows them to grab a market share quickly, but on the flip side, it can pose threats to patient safety and lead to serious regulatory issues.